digitalstudios2026-03-09T16:09:30+00:00MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
digitalstudios2026-03-09T16:00:45+00:00Medline Awards Distribution Center of the Year and SAFE Awards